Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status

Completed

Conditions

Hepatitis C

Study type

Observational

Funder types

Industry

Identifiers

NCT03071133
AI443-144

Details and patient eligibility

About

An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan

Enrollment

344 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who are initiating the treatment with DCV Trio therapy under the approved indications, dosage, and administration

Exclusion criteria

Patients who use the DCV Trio off label

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems